MB-105 is a CD5 CAR T cell technology. The asset developed at Baylor College of Medicine, is currently in the clinic for the treatment of T-cell lymphoma (TCL), which represents 15% of all non-Hodgkin lymphomas.
Although targeted and cellular immunotherapies have improved the management of B-cell leukemia and lymphoma, patients with treatment-resistant or recurrent T-cell cancers face limited options. The current standard of care relies on chemotherapy and hematopoietic stem cell transplants, with limited targeted therapies available due to shared targets between normal and malignant T- cells. Chemotherapy refractory T-cell malignancies face an extremely poor prognosis, with typically a less than 20% 3-year survival.
Challenging Targets for T Cell Malignancies
The main challenge in treating T-cell lymphoma or leukemia is the potential for on-target off-tumor activity, leading to undesirable side effects and severe immunodeficiency. A limitation that is faced also for CAR T cell therapy. The challenge remains due to the shared expression of targetable antigens between the malignant and normal T-cells.
CD5 as a Target
March Biosciences’ lead asset, MB-105, selectively targets CD5, a widely expressed antigen both in normal and malignant T- cells. Leveraging our proprietary manufacturing processes combined with an optimized CAR design, we are able to overcome key challenges for CAR T cell therapy.
November 13, 2019
October 27, 2017
August 20, 2015
March 5, 2019
Autologous CD5 CAR T, developed at Baylor College of Medicine, is currently being evaluated in a Phase 1 clinical trial (NCT03081910) for T-cell lymphoma and T-cell acute lymphoblastic leukemia (TCL and T-ALL). Initial results have revealed promising signals of safety and efficacy for these patients, who otherwise have limited treatment options. Enrollment for this trial is ongoing.
Clinical Trial Identifier: NCT03081910